NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.87 -0.04 (-0.05%) GOLD FUTURES
2,364.50 -2.00 (-0.08%) DOW
38,111.48 -330.06 (-0.86%) Bitcoin GBP
53,693.97 +585.57 (+1.10%)
Ikena Oncology, Inc. (IKNA)
After hours:
| Previous close | 1.6700 |
| Open | 1.7000 |
| Bid | 1.7700 x 400 |
| Ask | 1.8100 x 200 |
| Day's range | 1.7000 - 1.8500 |
| 52-week range | 1.0200 - 7.3800 |
| Volume | |
| Avg. volume | 332,856 |
| Market cap | 86.382M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5700 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
GlobeNewswireUPDATE – Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
- GlobeNewswire
Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
- GlobeNewswire
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provi
